{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T20:05:54Z","timestamp":1792785954426,"version":"4.5.0"},"reference-count":41,"publisher":"Oxford University Press (OUP)","issue":"Supplement_1","license":[{"start":{"date-parts":[[2020,12,22]],"date-time":"2020-12-22T00:00:00Z","timestamp":1608595200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Mectizan Donation Program"},{"name":"Global Alliance for LF Elimination"},{"DOI":"10.13039\/501100000265","name":"Medical Research Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000265","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000780","name":"European Union","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,12,22]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>The Global Programme to Eliminate Lymphatic Filariasis (GPELF) was established by the WHO in 2000. It aims to eliminate lymphatic filariasis as a public health problem. This paper summarises the key estimates of the cost-effectiveness and economic benefits related to the mass drug administration (MDA) provided by the GPELF. Several studies have investigated the cost-effectiveness of this MDA, estimating the cost per disability-adjusted life year (DALY) averted. These cost-effectiveness estimates have consistently classed the intervention as cost-effective and as favourable compared with other public health interventions conducted in low- and middle-income countries. Studies have also found that the MDA used for lymphatic filariasis control generates significant economic benefits. Although these studies are positive, there are still important gaps that warrant further health economic research (particularly, the evaluation of alternative interventions, further evaluation of morbidity management strategies and evaluation of interventions for settings coendemic with Loa loa). To conclude, health economic studies for a programme as large as the GPELF are subject to uncertainty. That said, the GPELF has consistently been estimated to be cost-effective and to generate notable economic benefits by a number of independent studies.<\/jats:p>","DOI":"10.1093\/inthealth\/ihaa095","type":"journal-article","created":{"date-parts":[[2020,10,28]],"date-time":"2020-10-28T16:13:27Z","timestamp":1603901607000},"page":"S71-S74","source":"Crossref","is-referenced-by-count":11,"title":["Health economic analyses of the Global Programme to Eliminate Lymphatic Filariasis"],"prefix":"10.1093","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8428-3874","authenticated-orcid":false,"given":"Hugo C","family":"Turner","sequence":"first","affiliation":[{"name":"MRC Centre for Global Infectious Disease Analysis, Department of Infectious Disease Epidemiology, School of Public Health, Faculty of Medicine, St Mary's Campus, Imperial College London, Norfolk Place, London, W2 1PG, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2020,12,22]]},"reference":[{"key":"2020122201493201200_bib1","volume-title":"Global Programme to Eliminate Lymphatic Filariasis","author":"World Health Organization"},{"key":"2020122201493201200_bib2","volume-title":"PCT databank: Lymphatic filariasis","author":"World Health Organization"},{"issue":"6","key":"2020122201493201200_bib3","first-page":"728","article-title":"Investment success in public health: An analysis of the cost-effectiveness and cost-benefit of the Global Programme to Eliminate Lymphatic Filariasis","volume":"64","author":"Turner","year":"2017","journal-title":"Clin Infect Dis"},{"issue":"1","key":"2020122201493201200_bib4","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1186\/s13071-018-2616-z","article-title":"Economic evaluations of lymphatic filariasis interventions: a systematic review and research needs","volume":"11","author":"Gedge","year":"2018","journal-title":"Parasites Vectors"},{"issue":"1","key":"2020122201493201200_bib5","doi-asserted-by":"crossref","first-page":"e67","DOI":"10.1371\/journal.pntd.0000067","article-title":"National mass drug administration costs for lymphatic filariasis elimination","volume":"1","author":"Goldman","year":"2007","journal-title":"PLoS Negl Trop Dis"},{"issue":"0","key":"2020122201493201200_bib6","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.actatropica.2014.03.017","article-title":"Lymphatic filariasis and onchocerciasis prevention, treatment, and control costs across diverse settings: A systematic review","volume":"135","author":"Keating","year":"2014","journal-title":"Acta Trop"},{"issue":"12","key":"2020122201493201200_bib7","doi-asserted-by":"crossref","first-page":"e0005037","DOI":"10.1371\/journal.pntd.0005037","article-title":"Benchmarks for the cost per person of mass treatment against neglected tropical diseases: a literature review and metaregression with web-based software application","volume":"10","author":"Fitzpatrick","year":"2016","journal-title":"PLoS Negl Trop Dis"},{"key":"2020122201493201200_bib8","first-page":"433","article-title":"Tropical diseases targeted for elimination: chagas disease, lymphatic dilariasis, onchocerciasis, and leprosy","volume-title":"Disease Control Priorities in Developing Countries","author":"Remme","year":"2006"},{"issue":"1","key":"2020122201493201200_bib9","doi-asserted-by":"crossref","first-page":"e000021","DOI":"10.1136\/bmjgh-2015-000021","article-title":"Modelling the health impact and cost-effectiveness of lymphatic filariasis eradication under varying levels of mass drug administration scale-up and geographic coverage","volume":"1","author":"Stone","year":"2016","journal-title":"BMJ Global Health"},{"issue":"8","key":"2020122201493201200_bib10","doi-asserted-by":"crossref","first-page":"e0182951","DOI":"10.1371\/journal.pone.0182951","article-title":"Ranking 93 health interventions for low- and middle-income countries by cost-effectiveness","volume":"12","author":"Horton","year":"2017","journal-title":"PLoS One"},{"issue":"6","key":"2020122201493201200_bib11","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1007\/s40273-014-0162-x","article-title":"Hutubessy R. Are current cost-effectiveness thresholds for low- and middle-income countries useful? Examples from the world of vaccines","volume":"32","author":"Newall","year":"2014","journal-title":"Pharmacoeconomics"},{"issue":"2","key":"2020122201493201200_bib12","doi-asserted-by":"crossref","first-page":"118","DOI":"10.2471\/BLT.14.138206","article-title":"Thresholds for the cost-effectiveness of interventions: alternative approaches","volume":"93","author":"Marseille","year":"2015","journal-title":"Bull World Health Organ"},{"issue":"8","key":"2020122201493201200_bib13","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1016\/j.jval.2016.02.017","article-title":"Country-level cost-effectiveness thresholds: initial estimates and the need for further research","volume":"19","author":"Woods","year":"2016","journal-title":"Value Health"},{"issue":"11","key":"2020122201493201200_bib14","doi-asserted-by":"crossref","first-page":"903","DOI":"10.2165\/10899580-000000000-00000","article-title":"Cost effectiveness in low- and middle-income countries: a review of the debates surrounding decision rules","volume":"27","author":"Shillcutt","year":"2009","journal-title":"Pharmacoeconomics"},{"issue":"7","key":"2020122201493201200_bib15","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1016\/j.jval.2017.12.016","article-title":"Use and misuse of cost-effectiveness analysis thresholds in low- and middle-income countries: trends in cost-per-DALY studies","volume":"21","author":"Leech","year":"2018","journal-title":"Value Health"},{"key":"2020122201493201200_bib16","volume-title":"Contribution of Pharmaceutical Companies to the Control of Neglected Tropical Diseases","author":"World Health Organization"},{"issue":"7","key":"2020122201493201200_bib17","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1111\/tmi.13241","article-title":"Economic evaluations of onchocerciasis interventions: a systematic review and research needs","volume":"24","author":"Turner","year":"2019","journal-title":"Trop Med Int Health"},{"issue":"2","key":"2020122201493201200_bib18","doi-asserted-by":"crossref","first-page":"e0004397","DOI":"10.1371\/journal.pntd.0004397","article-title":"Productivity loss related to neglected tropical diseases eligible for preventive chemotherapy: a systematic literature review","volume":"10","author":"Lenk","year":"2016","journal-title":"PLoS Negl Trop Dis"},{"issue":"6","key":"2020122201493201200_bib19","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/S0169-4758(00)01643-4","article-title":"The economic burden of lymphatic filariasis in India","volume":"16","author":"Ramaiah","year":"2000","journal-title":"Parasitol Today"},{"issue":"1","key":"2020122201493201200_bib20","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1080\/00034983.1996.11813024","article-title":"The economic burden of lymphatic filariasis in northern Ghana","volume":"90","author":"Gyapong","year":"1996","journal-title":"Ann Trop Med Parasitol"},{"issue":"12","key":"2020122201493201200_bib21","doi-asserted-by":"crossref","first-page":"2561","DOI":"10.1093\/cid\/ciz671","article-title":"The health and economic burdens of lymphatic filariasis prior to mass drug administration programs","volume":"70","author":"Mathew","year":"2020","journal-title":"Clin Infect Dis"},{"issue":"1","key":"2020122201493201200_bib22","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1186\/s40249-016-0147-4","article-title":"The health and economic benefits of the Global Programme to Eliminate Lymphatic Filariasis (2000\u20132014)","volume":"5","author":"Turner","year":"2016","journal-title":"Infect Dis Poverty"},{"issue":"6","key":"2020122201493201200_bib23","doi-asserted-by":"crossref","first-page":"e708","DOI":"10.1371\/journal.pntd.0000708","article-title":"The economic benefits resulting from the first 8 years of the Global Programme to Eliminate Lymphatic Filariasis (2000\u20132007)","volume":"4","author":"Chu","year":"2010","journal-title":"PLoS Negl Trop Dis"},{"issue":"1","key":"2020122201493201200_bib24","doi-asserted-by":"crossref","first-page":"e0005289","DOI":"10.1371\/journal.pntd.0005289","article-title":"The socioeconomic benefit to individuals of achieving the 2020 targets for five preventive chemotherapy neglected tropical diseases","volume":"11","author":"Redekop","year":"2017","journal-title":"PLoS Negl Trop Dis"},{"key":"2020122201493201200_bib25","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/1475-2883-6-2","article-title":"Morbidity management in the Global Programme to Eliminate Lymphatic Filariasis: a review of the scientific literature","volume":"6","author":"Addiss","year":"2007","journal-title":"Filaria J"},{"issue":"1","key":"2020122201493201200_bib26","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1046\/j.1365-3156.1999.00351.x","article-title":"Treatment costs and loss of work time to individuals with chronic lymphatic filariasis in rural communities in south India","volume":"4","author":"Ramaiah","year":"1999","journal-title":"Trop Med Int Health"},{"issue":"4","key":"2020122201493201200_bib27","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1080\/00034983.2000.11813550","article-title":"The impact of lymphatic filariasis on labour inputs in southern India: results of a multi-site study","volume":"94","author":"Ramaiah","year":"2000","journal-title":"Ann Trop Med Parasitol"},{"issue":"3","key":"2020122201493201200_bib28","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1093\/cid\/civ882","article-title":"Efficacy, safety, and pharmacokinetics of co-administered diethylcarbamazine, albendazole, and ivermectin for the treatment of Bancroftian filariasis","volume":"62","author":"Thomsen","year":"2016","journal-title":"Clin Infect Dis"},{"key":"2020122201493201200_bib29","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1146\/annurev.ento.54.110807.090626","article-title":"Role of vector control in the global program to eliminate lymphatic filariasis","volume":"54","author":"Bockarie","year":"2009","journal-title":"Annu Rev Entomol"},{"key":"2020122201493201200_bib30","article-title":"Provisional strategy for interrupting lymphatic filariasis transmission in loiasis-endemic countries: report of the meeting on lymphatic filariasis, malaria and integrated vector management","author":"World Health Organisation","year":"2012"},{"key":"2020122201493201200_bib31","volume-title":"Update on the Global Status of Implementation of Preventive Chemotherapy (PC)","author":"World Health Organization"},{"issue":"7","key":"2020122201493201200_bib32","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.pt.2006.05.007","article-title":"Projected benefits from integrating NTD programs in sub-Saharan Africa","volume":"22","author":"Brady","year":"2006","journal-title":"Trends Parasitol"},{"issue":"10","key":"2020122201493201200_bib33","doi-asserted-by":"crossref","first-page":"e317","DOI":"10.1371\/journal.pntd.0000317","article-title":"The Global Programme to Eliminate Lymphatic Filariasis: health impact after 8 years","volume":"2","author":"Ottesen","year":"2008","journal-title":"PLoS Negl Trop Dis"},{"key":"2020122201493201200_bib34","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1186\/s13071-015-0885-3","article-title":"Cost and cost-effectiveness of soil-transmitted helminth treatment programmes: systematic review and research needs","volume":"8","author":"Turner","year":"2015","journal-title":"Parasit Vectors"},{"key":"2020122201493201200_bib35","doi-asserted-by":"crossref","first-page":"45","DOI":"10.12688\/wellcomeopenres.15754.1","article-title":"Economic evaluations of human schistosomiasis interventions: a systematic review and identification of associated research needs [version 1; peer review: 2 approved]","volume":"5","author":"Turner","year":"2020","journal-title":"Wellcome Open Res"},{"issue":"7","key":"2020122201493201200_bib36","doi-asserted-by":"crossref","first-page":"e0004737","DOI":"10.1371\/journal.pntd.0004737","article-title":"Sustaining progress towards NTD elimination: an opportunity to leverage lymphatic filariasis elimination programs to interrupt transmission of soil-transmitted helminths","volume":"10","author":"Means","year":"2016","journal-title":"PLoS Negl Trop Dis"},{"issue":"11","key":"2020122201493201200_bib37","doi-asserted-by":"crossref","first-page":"e3281","DOI":"10.1371\/journal.pntd.0003281","article-title":"A comprehensive assessment of lymphatic filariasis in Sri Lanka six years after cessation of mass drug administration","volume":"8","author":"Rao","year":"2014","journal-title":"PLoS Negl Trop Dis"},{"issue":"3","key":"2020122201493201200_bib38","doi-asserted-by":"crossref","first-page":"e0008003","DOI":"10.1371\/journal.pntd.0008003","article-title":"Economic benefits and costs of surgery for filarial hydrocele in Malawi","volume":"14","author":"Sawers","year":"2020","journal-title":"PLoS Negl Trop Dis"},{"issue":"4","key":"2020122201493201200_bib39","doi-asserted-by":"crossref","first-page":"877","DOI":"10.4269\/ajtmh.16-0286","article-title":"Economic costs and benefits of a community-based lymphedema management program for lymphatic filariasis in Odisha State, India","volume":"95","author":"Stillwaggon","year":"2016","journal-title":"Am J Trop Med Hyg"},{"key":"2020122201493201200_bib40","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/s40249-015-0068-7","article-title":"The burden of mental health in lymphatic filariasis","volume":"4","author":"Ton","year":"2015","journal-title":"Infect Dis Poverty"},{"issue":"3","key":"2020122201493201200_bib41","doi-asserted-by":"crossref","first-page":"e0008058","DOI":"10.1371\/journal.pntd.0008058","article-title":"Quantifying the socio-economic impact of leg lymphoedema on patient caregivers in a lymphatic filariasis and podoconiosis co-endemic district of Ethiopia","volume":"14","author":"Caprioli","year":"2020","journal-title":"PLoS Negl Trop Dis"}],"container-title":["International Health"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/inthealth\/article-pdf\/13\/Supplement_1\/S71\/35056144\/ihaa095.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/inthealth\/article-pdf\/13\/Supplement_1\/S71\/35056144\/ihaa095.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,12,22]],"date-time":"2020-12-22T01:52:39Z","timestamp":1608601959000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/inthealth\/article\/13\/Supplement_1\/S71\/6043675"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12,22]]},"references-count":41,"journal-issue":{"issue":"Supplement_1","published-online":{"date-parts":[[2020,12,22]]},"published-print":{"date-parts":[[2020,12,22]]}},"URL":"https:\/\/doi.org\/10.1093\/inthealth\/ihaa095","relation":{},"ISSN":["1876-3413","1876-3405"],"issn-type":[{"value":"1876-3413","type":"print"},{"value":"1876-3405","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,1]]},"published":{"date-parts":[[2020,12,22]]}}}